# Oxaliplatin, Capecitabine, and Cetuximab in Treating Patients With Advanced Liver Cancer

> **NCT00483405** · PHASE2 · COMPLETED · sponsor: **UNC Lineberger Comprehensive Cancer Center** · enrollment: 33 (actual)

## Conditions studied

- Liver Cancer

## Interventions

- **BIOLOGICAL:** cetuximab
- **DRUG:** capecitabine
- **DRUG:** oxaliplatin

## Key facts

- **NCT ID:** NCT00483405
- **Lead sponsor:** UNC Lineberger Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** 2010-02
- **Final completion:** 2010-12
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2017-07-12

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00483405

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00483405, "Oxaliplatin, Capecitabine, and Cetuximab in Treating Patients With Advanced Liver Cancer". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00483405. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*